Hyphen BioMed Literature
Product Price Catalogue
Interactive Poster(s)
Blood Coagulation Poster
-
- Activation, Regulation, Inhibition of Blood Coagulation Poster with Corresponding Products
Author: HYPHEN BioMed, February 2010
- Activation, Regulation, Inhibition of Blood Coagulation Poster with Corresponding Products
HEMOCLOT
HEMOCLOT – Schemes
-
- The Modern Approach for Clotting Assays
Author: HYPHEN BioMed, September 2009
- The Modern Approach for Clotting Assays
Direct Thrombin Inhibitors
-
-
- Dabigatran Calibrator and Control Plasmas for Drug Measurement in Plasma, When Required (Ref. A222801, A224701)
Author: J. Amiral, M. Peyrafitte – HYPHEN BioMed & Stangier J. – Boehringer Ingelheim Pharma Gmbh & Co KG, GTH – February 2011
- Dabigatran Calibrator and Control Plasmas for Drug Measurement in Plasma, When Required (Ref. A222801, A224701)
-
-
-
- Interference of Routine Coagulation Tests with the New Oral Anticoagulant Dabigatran – A Multicenter Study. (Ref. A222801, A224701)
Author: Weigel G., Loacker L.J. , Griesmacher A. , Tomasits J, Halbmayer W.M., Quehenberger P., Aspöck G., Haushofer A., 2011
- Interference of Routine Coagulation Tests with the New Oral Anticoagulant Dabigatran – A Multicenter Study. (Ref. A222801, A224701)
-
-
-
- New Assays for Measuring Direct Thrombin Inhibitors in Plasma (Ref. ACK002K, ACK002L, ASC030K, ASC035K)
Author: M. Peyrafitte, A.M. Vissac, J. Amiral – HYPHEN BioMed, ISTH – July 2009
- New Assays for Measuring Direct Thrombin Inhibitors in Plasma (Ref. ACK002K, ACK002L, ASC030K, ASC035K)
-
-
- Direct Thrombin Inhibitors’ Activity Measurement in Plasma (ref. ASC030K, ASC035K, ACK002K, ACK002L, A220202)
Author: M. Peyrafitte, A.M. Vissac, J. Amiral – HYPHEN BioMed, February 2009
- Direct Thrombin Inhibitors’ Activity Measurement in Plasma (ref. ASC030K, ASC035K, ACK002K, ACK002L, A220202)
Protein C / Protein S and AT III Pathways
-
- Highly Stable and Robust Protein S Clotting Assay Validated for an Easier Laboratory Practice (Ref. ACK041K)
Author: M. Peyrafitte, A.M. Vissac, J. Amiral – HYPHEN BioMed, GTH – February 2011
- Highly Stable and Robust Protein S Clotting Assay Validated for an Easier Laboratory Practice (Ref. ACK041K)
Factor V-Leiden
-
-
- Evaluation of a Novel Quantitative Assay for Factor V Leiden (Ref. ACK065K)
Author: Hickey KP, Cooper PC, Kitchen S. – Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, February 2010
- Evaluation of a Novel Quantitative Assay for Factor V Leiden (Ref. ACK065K)
-
-
- Quantitative Measurement of Factor V Leiden in Heterozygous and Homozygous Patients for the R506Q Factor V Mutation (Ref. ACK065K, ACK071, ARK009A)
Author: AM. Vissac, M. Peyrafitte, J. Amiral – HYPHEN BioMed, C. Leroy-Matheron – Lab Hémostase, GTH – February 2009
- Quantitative Measurement of Factor V Leiden in Heterozygous and Homozygous Patients for the R506Q Factor V Mutation (Ref. ACK065K, ACK071, ARK009A)
BIOPHEN
Factor VIII:C
-
- Factors Affecting the Factor VIII:C Reactivity When Tested in Purified Systems With Chromogenic Assays (Ref. A221402)
Author: Amiral J, Vissac AM – HYPHEN BioMed, July 2007
- Factors Affecting the Factor VIII:C Reactivity When Tested in Purified Systems With Chromogenic Assays (Ref. A221402)
Anti-Xa Heparin Assays
-
- Comparison of Two Anti-Xa Heparin Assays That Use a Single (Hybrid) Calibration Curve for Unfractionated and Low Molecular Weight Heparin (Ref. A221010)
Author: McGlasson DL, Fritsma GA – Wilford Hall Medical Center, June 2007
- Comparison of Two Anti-Xa Heparin Assays That Use a Single (Hybrid) Calibration Curve for Unfractionated and Low Molecular Weight Heparin (Ref. A221010)
Factor IX and X
-
- New Standardized Chromogenic Assays for Automated Measurements of FIX or FIXa in Plasma and Therapeutic Concentrates (Ref. A221802, A221806, A221812)
Author: M. Peyrafitte, A.M. Vissac, J. Amiral – HYPHEN BioMed, GTH – February 2009
- New Standardized Chromogenic Assays for Automated Measurements of FIX or FIXa in Plasma and Therapeutic Concentrates (Ref. A221802, A221806, A221812)
Direct Xa Inhibitors
-
-
- BIOPHEN DiXaI – For the Quantitative Determination of Direct Factor Xa Inhibitors in Plasma
Author: Kris Van Assche – Nodia, Bayer – Belgium, February 2012
- BIOPHEN DiXaI – For the Quantitative Determination of Direct Factor Xa Inhibitors in Plasma
-
-
-
- Specific and Rapid Measurement of Rivaroxaban in Plasma using a New, Dedicated, Chromogenic Assay
Author: Samama M.M., Amiral J., Guinet C., Perzborn E., Depasse F. – Hotel Dieu University Hospital, HYPHEN BioMed, Biomnis Laboratories R&D, Research, Bayer HealthCare, GTH – February 2010
- Specific and Rapid Measurement of Rivaroxaban in Plasma using a New, Dedicated, Chromogenic Assay
-
-
- BIOPHEN DiXaI Powerpoint (Ref. A221030)
Author: Jonas Kingo – Aniara, February 2010
- BIOPHEN DiXaI Powerpoint (Ref. A221030)
ZYMUTEST
ZYMUTEST – Schemes
-
-
- Development of an Individual Anti-Factor VIII Inhibitors ELISA to Improve Hemophiliacs Therapeutic Follow Up (Ref. ARK039A)
Author: Peyrafitte M., Vissac A.M., Amiral J. – HYPHEN BioMed, GTH – February 2011
- Development of an Individual Anti-Factor VIII Inhibitors ELISA to Improve Hemophiliacs Therapeutic Follow Up (Ref. ARK039A)
-
-
-
- Fibrinolysis Mechanisms – Characteristics of Proteins Involved in Fibrinolysis
Author: HYPHEN BioMed, April 2010
- Fibrinolysis Mechanisms – Characteristics of Proteins Involved in Fibrinolysis
-
-
-
- Exploring Fibrinolysis with Today’s Technologies
Author: HYPHEN BioMed, April 2010
- Exploring Fibrinolysis with Today’s Technologies
-
-
- Fibrinolysis and Thrombosis Enzyme Immuno Assays for the Exploration of Fibrinolysis in Human Plasma (Ref. ZYMUTEST line / Rat Immunochemicals / Rat Biochemicals)
Author: Véronique Penissard – HYPHEN BioMed, April 2006
- Fibrinolysis and Thrombosis Enzyme Immuno Assays for the Exploration of Fibrinolysis in Human Plasma (Ref. ZYMUTEST line / Rat Immunochemicals / Rat Biochemicals)
Von Wilebrand Factor
-
- Evaluation of a New Collagen Binding Assay (Ref. ARK038A)
Author: Kappert G, Rott H, Halimeh S, January 2012
- Evaluation of a New Collagen Binding Assay (Ref. ARK038A)
Cross-Reactivities with Animal Proteins
-
- Cross-Reactivities with Homologous Animal Proteins for the Various ZYMUTEST Kits
Author: HYPHEN BioMed, August 2008
- Cross-Reactivities with Homologous Animal Proteins for the Various ZYMUTEST Kits
HIT Assays
-
-
- Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH
Authors: Johannes Oldenburg, Robert Klamroth, Florian Langer, Manuela Albisetti, Charis von Auer, Cihan Ay, Wolfgang Korte, Rüdiger E. Scharf, Bernd Pötzsch1 Andreas Greinacher
- Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH
-
-
-
- Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)
Authors: Johannes Thaler, Cihan Ay, Karoline V. Gleixner, Alexander W. Hauswirth, Filippo Cacioppo, Jürgen Grafeneder, Peter Quehenberger, Ingrid Pabinger, Paul Knöbl
- Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)
-
-
-
- ZYMUTEST HIA (IgG or IgGAM)
Author: Hyphen BioMed, October 2007
- ZYMUTEST HIA (IgG or IgGAM)
-
-
-
- ZYMUTEST HIA Algorithm (Ref. ARK040A)
Author: Hans G. Zwerger – CoaChrom Diagnostica – March 2013
- ZYMUTEST HIA Algorithm (Ref. ARK040A)
-
-
-
- Antibodies to Protamine Sulfateor to its Complexes with Heparin can be the Sole Ones Identified in Some Patients with Suspicion of HIT
Author: Amiral J., Vissac A.M. – HYPHEN BioMed, GTH – February 2010
- Antibodies to Protamine Sulfateor to its Complexes with Heparin can be the Sole Ones Identified in Some Patients with Suspicion of HIT
-
-
-
- Heterogenity of Heparin Induced Antibody Profiles in Patients Suspected of Heparin Induced Thrombocytopenia (HIT)
Author: Vissac A.M., Amiral J. – HYPHEN BioMed, GTH – February 2010
- Heterogenity of Heparin Induced Antibody Profiles in Patients Suspected of Heparin Induced Thrombocytopenia (HIT)
-
-
-
- Can We Improve Clinical Specificity for HIT Immunoassays? (Ref. ARK040A, ARK040B, ARK040C, ARK040D, ARK040E, ARK041A, ARK041D)
Author: A.M. Vissac, J. Amiral – HYPHEN BioMed, ISTH – July 2009
- Can We Improve Clinical Specificity for HIT Immunoassays? (Ref. ARK040A, ARK040B, ARK040C, ARK040D, ARK040E, ARK041A, ARK041D)
-
-
-
- Improved Clinical Specificity of Heparin Induced Thrombocytopenia Immunoassay (Ref. ARK040A, ARK040B, ARK040C, ARK040D, ARK040E)
Author: AM. Vissac, M. Peyrafitte, J. Amiral – HYPHEN BioMed, GTH – February 2009
- Improved Clinical Specificity of Heparin Induced Thrombocytopenia Immunoassay (Ref. ARK040A, ARK040B, ARK040C, ARK040D, ARK040E)
-
-
-
- Association of Protamine Sulfate Antibodies with “Pseudo-HIT” in Heparin Treated Patients (Ref. ARK040A, ARK040B, ARK040C, ARK040D, ARK040E)
Author: J. Amiral, AM. Vissac – HYPHEN BioMed, GTH – February 2009
- Association of Protamine Sulfate Antibodies with “Pseudo-HIT” in Heparin Treated Patients (Ref. ARK040A, ARK040B, ARK040C, ARK040D, ARK040E)
-
-
-
- New Approach for Detection Of Heparin Dependent Antibodies and Risk Assessment for Heparin Induced Thrombocytopenia – HIT Assays
Author: Amiral J, Peyrafitte M, Catala M, Vissac AM – HYPHEN BioMed, July 2007
- New Approach for Detection Of Heparin Dependent Antibodies and Risk Assessment for Heparin Induced Thrombocytopenia – HIT Assays
-
-
- Incidence of the Various Heparin Dependent Antibody Isotypes in a Group of Patients With Heparin Induced Thrombocytopenia – HIT Assays
Author: Vissac AM, Catala M, Amiral J, – HYPHEN BioMed, July 2007
- Incidence of the Various Heparin Dependent Antibody Isotypes in a Group of Patients With Heparin Induced Thrombocytopenia – HIT Assays
Microparticles
-
-
- Microparticles Exposing Tissue Factor in Human Plasma (Ref. A521196)
Author: Laroche M., Peyrafitte M., Vissac A.M. , Amiral J. – HYPHEN BioMed, GTH – February 2011
- Microparticles Exposing Tissue Factor in Human Plasma (Ref. A521196)
-
-
-
- The Multiple Faces of Tissue Factor Measured with Laboratory Assays (Ref. A521196, ARK035A, ARK042A)
Author: Laroche M., Peyrafitte M., Vissac A.M. , Amiral J. – HYPHEN BioMed, GTH – February 2011
- The Multiple Faces of Tissue Factor Measured with Laboratory Assays (Ref. A521196, ARK035A, ARK042A)
-
-
- Microparticles Procoagulant Activity in Citrated Plasma (Ref. A521096)
Author: AM. Vissac, M. Peyrafitte, J. Amiral – HYPHEN BioMed, July 2007
- Microparticles Procoagulant Activity in Citrated Plasma (Ref. A521096)
Technical Files
Heparin Kits
-
-
- BIOPHEN Heparin (LRT) Technical File (Ref. A221011)
Author: HYPHEN BioMed, July 2010
- BIOPHEN Heparin (LRT) Technical File (Ref. A221011)
-
-
-
- BIOPHEN Heparin Anti-Xa (2 stages) USP/EP Technical File (Ref. A221010-USP)
Author: Véronique Penissard – HYPHEN BioMed, February 2010
- BIOPHEN Heparin Anti-Xa (2 stages) USP/EP Technical File (Ref. A221010-USP)
-
-
-
- BIOPHEN Heparin Anti-IIa (2 Stages) – USP/EP Technical File (Ref. A221025-USP)
Author: Véronique Penissard – HYPHEN BioMed, February 2010
- BIOPHEN Heparin Anti-IIa (2 Stages) – USP/EP Technical File (Ref. A221025-USP)
-
-
- BIOPHEN Heparin Technical File (Ref. A221003, A221006)
Author: Jean Amiral – HYPHEN BioMed, May 2006
- BIOPHEN Heparin Technical File (Ref. A221003, A221006)
Rivaroxaban
-
- Rivaroxaban Technical File (Ref. A222701, A224501)
Author: Laetitia FRANK – HYPHEN BioMed, April 2012
- Rivaroxaban Technical File (Ref. A222701, A224501)
Chromogenic Kits
-
-
- BIOPHEN Arixtra Technical File (Ref. A224001, A222501)
Author: HYPHEN BioMed, July 2010
- BIOPHEN Arixtra Technical File (Ref. A224001, A222501)
-
-
-
- BIOPHEN DiXaI (Direct Inhibitors) Technical File (Ref. A221030)
Author: HYPHEN BioMed, October 2009
- BIOPHEN DiXaI (Direct Inhibitors) Technical File (Ref. A221030)
-
-
-
- BIOPHEN Antithrombin (AT) Technical File (Ref. A221102, A221105)
Author: Véronique Penissard – HYPHEN BioMed, August 2009
- BIOPHEN Antithrombin (AT) Technical File (Ref. A221102, A221105)
-
-
-
- BIOPHEN Protein C Technical File (Ref. A221205)
Author: Véronique Penissard – HYPHEN BioMed, August 2009
- BIOPHEN Protein C Technical File (Ref. A221205)
-
-
-
- BIOPHEN Factor VIII:C Technical File (Ref. A221402, A221406)
Author: Véronique Penissard – HYPHEN BioMed, August 2009
- BIOPHEN Factor VIII:C Technical File (Ref. A221402, A221406)
-
-
- BIOPHEN Factor X Technical File (Ref. A221705)
Author: Jean Amiral – HYPHEN BioMed, April 2006
- BIOPHEN Factor X Technical File (Ref. A221705)
CEPHEN Kits
-
- CEPHEN Technical File (Ref. ACK511K, ACK512K, ACK515K, ACK515L, ACK521K & ACK522K)
Author: Véronique Penissard – HYPHEN BioMed, September 2009
- CEPHEN Technical File (Ref. ACK511K, ACK512K, ACK515K, ACK515L, ACK521K & ACK522K)
HEMOCLOT Kits
-
-
- Protein S Technical File (Ref. ACK041K)
Author: Laetitia Frank – HYPHEN BioMed, April 2012
- Protein S Technical File (Ref. ACK041K)
-
-
-
- HEMOCLOT Thrombin Inhibitors Technical File (Ref. ACK002K, ACK002L)
Author: HYPHEN BioMed, November 2010
- HEMOCLOT Thrombin Inhibitors Technical File (Ref. ACK002K, ACK002L)
-
-
-
- HEMOCLOT Protein C Technical File (Ref. ACK031K)
Author: HYPHEN BioMed, July 2010
- HEMOCLOT Protein C Technical File (Ref. ACK031K)
-
-
- HEMOCLOT Thrombin Time (T.T.) Technical File (Ref. ACK011K, ACK011L)
Author: Peyrafitte M. – HYPHEN BioMed, July 2006
- HEMOCLOT Thrombin Time (T.T.) Technical File (Ref. ACK011K, ACK011L)
LIAPHEN
-
-
- LIAPHEN AT Technical File (Ref. A120002)
Author: HYPHEN BioMed, October 2011
- LIAPHEN AT Technical File (Ref. A120002)
-
-
- LIAPHEN Fibrinogen Technical File – CE (Ref. A120102)
Author: HYPHEN BioMed, March 2011
- LIAPHEN Fibrinogen Technical File – CE (Ref. A120102)
ZYMUTEST Kits
-
-
- ZYMUTEST Anti B2GPI IgG/IgM Technical File (Ref. ARK014A,ARK014B)
Author: Véronique Penissard – HYPHEN BioMed, August 2009
- ZYMUTEST Anti B2GPI IgG/IgM Technical File (Ref. ARK014A,ARK014B)
-
-
-
- ZYMUTEST PAI-1 Antigen Technical File (Ref. ARK012A)
Author: Jean Amiral – HYPHEN BioMed, May 2006
- ZYMUTEST PAI-1 Antigen Technical File (Ref. ARK012A)
-
-
- ZYMUTEST tPA Antigen Technical File (Ref. ARK011A)
Author: Jean Amiral – HYPHEN BioMed, May 2006
- ZYMUTEST tPA Antigen Technical File (Ref. ARK011A)
Evaluation of Hyphen BioMed Chromogenic Substrates vs Chromogenix Substrates
-
-
- Comparison of Characteristics and Performances of Thrombin Chromogenic Substrates: Hyphen BioMed CS-01(38) vs Chromogenix S2238 (Ref. A229001, A229001-100, A229001-1, A229001-5)
Author: M. Peyrafitte – HYPHEN BioMed, April 2009
- Comparison of Characteristics and Performances of Thrombin Chromogenic Substrates: Hyphen BioMed CS-01(38) vs Chromogenix S2238 (Ref. A229001, A229001-100, A229001-1, A229001-5)
-
-
-
- Comparison of Characteristics and Performances of FXa Chromogenic Substrate: Hyphen BioMed CS-11(22) vs Chromogenix S2222 (Ref. A229015, A229115, A229015-1, A229015-5)
Author: M. Peyrafitte – HYPHEN BioMed, April 2009
- Comparison of Characteristics and Performances of FXa Chromogenic Substrate: Hyphen BioMed CS-11(22) vs Chromogenix S2222 (Ref. A229015, A229115, A229015-1, A229015-5)
-
-
-
- Comparison of Characteristics and Performance of FXa Chromogenic Substrate: Hyphen BioMed CS-11(32) vs Chromogenix S2732 (Ref. A229011, A229011-100, A229011-1, A229011-5)
Author: M. Peyrafitte – HYPHEN BioMed, April 2009
- Comparison of Characteristics and Performance of FXa Chromogenic Substrate: Hyphen BioMed CS-11(32) vs Chromogenix S2732 (Ref. A229011, A229011-100, A229011-1, A229011-5)
-
-
-
- Comparison of Characteristics and Performances of FXa Chromogenic Substrate : Hyphen BioMed CS-11(65) vs Chromogenix S2765 (Ref. A229014, A229014-100, A229014-1, A229014-5)
Author: M. Peyrafitte – HYPHEN BioMed, April 2009
- Comparison of Characteristics and Performances of FXa Chromogenic Substrate : Hyphen BioMed CS-11(65) vs Chromogenix S2765 (Ref. A229014, A229014-100, A229014-1, A229014-5)
-
-
-
- Comparison of Characteristics and Performances of Activated Protein C (aPC) Chromogenic Substrate: Hyphen BioMed CS-21(66) vs Chromogenix S2366 (Ref. A229021, A229021-100, A229021-1, A229021-5)
Author: M. Peyrafitte – HYPHEN BioMed, April 2009
- Comparison of Characteristics and Performances of Activated Protein C (aPC) Chromogenic Substrate: Hyphen BioMed CS-21(66) vs Chromogenix S2366 (Ref. A229021, A229021-100, A229021-1, A229021-5)
-
-
-
- Comparison of Characteristics and Performances of Plasmin/Plasminogen-SK Chromogenic Substrate: Hyphen BioMed CS-41(03) vs Chromogenix S2403 (Ref. A229041, A229041-100, A229041-1, A229041-5)
Author: M. Peyrafitte – HYPHEN BioMed, April 2009
- Comparison of Characteristics and Performances of Plasmin/Plasminogen-SK Chromogenic Substrate: Hyphen BioMed CS-41(03) vs Chromogenix S2403 (Ref. A229041, A229041-100, A229041-1, A229041-5)
-
-
-
- Comparison of Characteristics and Performances of Urokinase (uPA) Chromogenic Substrate: Hyphen BioMed CS-61(44) (Ref. A229061, A229061-100, A229061-1, A229061-5)
Author: M. Peyrafitte – HYPHEN BioMed, April 2009
- Comparison of Characteristics and Performances of Urokinase (uPA) Chromogenic Substrate: Hyphen BioMed CS-61(44) (Ref. A229061, A229061-100, A229061-1, A229061-5)
-
-
- Evaluation of chromogenic substrates: Hyphen BioMed vs Chromogenix – All Substrates
Author: HYPHEN BioMed, February 2008
- Evaluation of chromogenic substrates: Hyphen BioMed vs Chromogenix – All Substrates